Joe S. Mendez, MD

Journal Article

1. Mendez J, Cohen AL, Eckenstein M, Jensen RL, Burt LM, Salzman KL, Chamberlain M, Hsu HH, Hutchinson M, Iwamoto F, Ligon KL, Mrugala MM, Pelayo M, Plotkin SR, Pdudyalli VK, Raizer J, Reardon DA, Sterba M, Walbert T, Wong ET, Zhang C, Colman H (In Press). Phase 1b/2 Study of Orally Administered Pexidartinib in Combination with Radiation Therapy and Temozolomide in Patients with Newly Diagnosed Glioblastoma. (Epub ahead of print) Neurooncol Adv.
2. Mendez JS, Cohen AL, Eckenstein M, Jensen RL, Burt LM, Salzman KL, Chamberlain M, Hsu HH, Hutchinson M, Iwamoto F, Ligon KL, Mrugala MM, Pelayo M, Plotkin SR, Puduvalli VK, Raizer J, Reardon DA, Sterba M, Walbert T, West BL, Wong ET, Zhang C, Colman H (2024). Phase 1b/2 Study of Orally Administered Pexidartinib in Combination with Radiation Therapy and Temozolomide in Patients with Newly Diagnosed Glioblastoma. Neuro-Oncology Advances, vdae202, 2632-2498.
3. Salah WK, Findlay MC, Baker CM, Scoville JP, Bounajem MT, Ogilvy CS, Moore JM, Riina HA, Levy EI, Siddiqui AH, Spiotta AM, Cawley CM, Khalessi AA, Tanweer O, Hanel R, Gross BA, Kuybu O, Howard BM, Hoang AN, Baig AA, Khorasanizadeh M, Mendez Ruiz AA, Cortez G, Davies JM, Lang MJ, Thomas AJ, Tonetti DA, Khalife J, Sioutas GS, Carroll K, Abecassis ZA, Jankowitz BT, Ruiz Rodriguez J, Levitt MR, Kan PT, Burkhardt JK, Srinivasan V, Salem MM, Grandhi R (2024). The Influence of Coagulopathy on Radiographic and Clinical Outcomes in Patients Undergoing Middle Meningeal Artery Embolization as Standalone Treatment for Non-acute Subdural Hematomas. Journal of Neurotrauma, 41(11-12), 1375-1383.
4. Robinson LJ, Goold E, Cannon DM, Mendez JS, Menacho ST, Mao Q, Liu T (2024). A rare case of an adult primary intracranial sarcoma associated with a DICER1 mutation. J Neuropathol Exp Neurol, 83(5), 365-369. (Read full article)
5. Arnold L, Hoshina Y, Hyejung L, Haaland B, Colman H, Mendez JS (2024). Effect of Pneumocystis jirovecii Pneumonia Prophylaxis on Hematologic Toxicity in Patients Receiving Chemoradiation for Primary BrainTumors. J Neurooncol, 167(1), 211-217.
6. Mellinghoff IK, van den Bent MJ, Blumenthal DT, Touat M, Peters KB, Clarke J, Mendez J, Yust-Katz S, Welsh L, Mason WP, Ducray F, Umemura Y, Nabors B, Holdhoff M, Hottinger AF, Arakawa Y, Sepulveda JM, Wick W, Soffietti R, Perry JR, Giglio P, de la Fuente M, Maher EA, Schoenfeld S, Zhao D, Pandya SS, Steelman L, Hassan I, Wen PY, Cloughesy TF (2023). Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma. N Engl J Med, 389(7), 589-601. (Read full article)
7. Earl ER, Colman H, Mendez J, Jensen RL, Karsy M (2023). An evaluation of biobanking and therapeutic clinical trial representation among adult glioma patients from rural and urban Utah. Neurooncol Pract, 10(5), 472-481. (Read full article)
8. Lucas CG, Davidson CJ, Alashari M, Putnam AR, Whipple NS, Bruggers CS, Mendez JS, Cheshier SH, Walker JB, Ramani B, Cadwell CR, Sullivan DV, Lu R, Mirchia K, Van Ziffle J, Devine P, Goldschmidt E, Hervey-Jumper SL, Gupta N, Oberheim Bush NA, Raleigh DR, Bollen A, Tihan T, Pekmezci M, Solomon DA, Phillips JJ, Perry A (2023). Targeted Next-Generation Sequencing Reveals Divergent Clonal Evolution in Components of Composite Pleomorphic Xanthoastrocytoma-Ganglioglioma. J Neuropathol Exp Neurol, 81(8), 650-657. (Read full article)
9. Gelhard S, Maxwell A, Colman H, Cohen AL, Mendez JS (2022). Consolidation regimens in primary central nervous system lymphoma: a single-center retrospective cohort evaluating survival outcomes and cost-benefit analysis. J Neurooncol, 159(2), 293-300. (Read full article)
10. Kraus RD, Weil CR, Su FCF, Cannon DM, Burt LM, Mendez JS (2022). Incidence and extent of disease progression on MRI between surgery and initiation of radiotherapy in glioblastoma patients. Neurooncol Pract, 9(5), 380-389. (Read full article)
11. Guney E, Lucas CG, Qi Z, Yu J, Zhang R, Ohgami RS, Rubenstein JL, Bou DR, Schafernak KT, Wertheim GB, Dahiya S, Giulino-Roth L, Attarbaschi A, Barth MJ, Kothari S, Abla O, Cohen AL, Mendez JS, Bollen AW, Perry A, Tihan T, Pekmezci M, Solomon DA, Wen KW (2022). A genetically distinct pediatric subtype of primary CNS large B-cell lymphoma is associated with favorable clinical outcome. Blood Adv, 6, 3189-3193. (Read full article)
12. Parsons MW, Whipple NS, Poppe MM, Mendez JS, Cannon DM, Burt LM (2020). The use and efficacy of chemotherapy and radiotherapy in children and adults with pilocytic astrocytoma. J Neurooncol, 151(2), 93-101. (Read full article)
13. Mendez JS, Ostrom QT, Gittleman H, Kruchko C, DeAngelis LM, Barnholtz-Sloan JS, Grommes C (2018). The elderly left behind – Changes in survival trends of primary central nervous system lymphoma over the past four decades. Neuro Oncol, 20(5), 687-694.
14. Sneed PK, Mendez J, Vemer-van den Hoek JG, Seymour ZA, Ma L, Molinaro AM, Fogh SE, Nakamura JL, McDermott MW (2015). Adverse radiation effect after stereotactic radiosurgery for brain metastases: incidence, time course, and risk factors. J Neurosurg, 123(2), 373-86. (Read full article)

Review

1. Kropp S, Mendez JS (2024). Advancements in Targeted Molecular Therapy for Low-Grade Gliomas: Challenging the Treatment Paradigm. [Review]. Practical Neurology, 23(3), 56-59.
2. Azab MA, Cole K, Earl E, Cutler C, Mendez J, Karsy M (2023). Medical Management of Meningiomas. [Review]. Neurosurg Clin N Am, 34(3), 319-333. (Read full article)

Huntsman Cancer Institute News

• Talks with Docs: Joe Mendez, MD
• Clinical Trial Gives Hope to Patient Diagnosed with Brain Tumor

• Open-Label Phase II Study to Investigate the Efficacy, Safety, and Pharmacokinetics of Tirabrutinib in Patients with Primary Central Nervous System Lymphoma (PCNSL)
• ONC201 for the Treatment of Newly Diagnosed H3 K27M-Mutant Diffuse Glioma Following Completion of Radiotherapy: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study
• ONC201 for the Treatment of Newly Diagnosed H3 K27M-Mutant Diffuse Glioma Following Completion of Radiotherapy: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study
• Phase I, Safety Lead-In and Randomized, Open-Label, Perioperative Study of Vorasidenib in Combination with Pembrolizumab in Subjects with Recurrent or Progressive IDH-1 Mutant Astrocytomas
• Phase I, Safety Lead-In and Randomized, Open-Label, Perioperative Study of Vorasidenib in Combination with Pembrolizumab in Subjects with Recurrent or Progressive IDH-1 Mutant Astrocytomas
• Phase I, Safety Lead-In and Randomized, Open-Label, Perioperative Study of Vorasidenib in Combination with Pembrolizumab in Subjects with Recurrent or Progressive IDH-1 Mutant Astrocytomas
• Phase I, Safety Lead-In and Randomized, Open-Label, Perioperative Study of Vorasidenib in Combination with Pembrolizumab in Subjects with Recurrent or Progressive IDH-1 Mutant Astrocytomas
• Phase I/II Combination Study of NMS-03305293 and Temozolomide in Adult Patients with Recurrent Glioblastoma
• Vorasidenib Expanded Access Protocol in Patients with IDH1 or IDH2 Mutated Glioma
• An Open-Label, Dose Escalation and Dose Expansion Trial Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of Orally Administered CA-4948 in Patients with Relapsed or Refractory Primary Central Nervous System Lymphoma